UCB (EBR:UCB) UCB Media Room – UCB Showcases Wealth of new Psoriasis Research at EADV 2019

Directive transparence : information réglementée

09/10/2019 07:00
https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W2= 7HkUdGSImvHQ6Hnxedhbf51v5xTz8YVKU3FhdBqzS-2BRdzYmJv6OXWACDlRrfJH2M8vbhq-2FS= vUvBFGoKlds67-2Fguql-2FG-2Bj9su7sj2p5V_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re= 5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsAC= RMW7oN5ofytBygtIFD3oaokb2us3k7AJy441T7WNxPPVTv821BriKESvLaQypbwTNG2Lk7UYD-2= FkK-2BhyeslUT59CViG1HmxaAGzYhd36-2F3qp-2FNx6i9FeFRgoEIA0mT1OXuoPLt-2F9UuKkM= xRrKaXK8gkTWAzvcuF9N-2BUhPbe817yI4OsGk3GSGqzqlTMBdNg24JCGm1TbsYcjRGdh5QnjID= MCdaoX1WZyl5SfPKyRyqUTtXgggUR00NmCP1yy1XRO4-3D ** UCB Showcases Wealth of new Psoriasis Research at EADV 2019 ------------------------------------------------------------ =C2=B7 Data to be presented at EADV 2019 will further confirm the durabilit= y of CIMZIA=C2=AE (certolizumab pegol) treatment in moderate-to-severe plaq= ue psoriasis, including new three-year efficacy data =C2=B7 New positive 60-week outcomes data from Phase 2 studies underscore t= he potential of bimekizumab to improve scalp and nail psoriasis and health-= related quality of life in psoriasis patients =C2=B7 In total, UCB will present nine abstracts at the meeting, demonstrat= ing the company=E2=80=99s ongoing commitment to improving the lives of peop= le with psoriasis and psoriatic arthritis Brussels, Belgium =E2=80=93 9 October 2019 =E2=80=93 UCB, a global biopharm= aceutical company, today announced new data on the use of the Fc-free anti-= TNF treatment, CIMZIA^=C2=AE (certolizumab pegol), in psoriasis and psoriat= ic arthritis (PsA) will be presented at the 28th European Academy of Dermat= ology and Venereology congress (EADV) in Madrid, October 9-13, 2019. Data i= nclude three-year outcomes in psoriasis^1 and four-year results in PsA from= the open-label extension studies of CIMZIA.^2 Additionally, the company wi= ll share 60-week results^3,4 from the Phase 2 clinical development program = of the company=E2=80=99s pipeline molecule bimekizumab =E2=80=93 a novel hu= manized monoclonal IgG1 antibody that potently and selectively neutralizes = both IL-17A and IL-17F cytokines, thought to be key drivers of psoriasis.^5 =E2=80=9CResults presented at EADV 2019 will reinforce and support the dura= bility profile of CIMZIA efficacy in the treatment of both psoriasis and ps= oriatic arthritis, and provide further evidence as to the exciting potentia= l of bimekizumab in psoriasis,=E2=80=9D said Emmanuel Caeymaex, Head of Imm= unology and Executive Vice President, Immunology Patient Value Unit, UCB. = =E2=80=9CPatients with psoriasis deserve rapid and sustainable treatment re= sults. The data we will share in Madrid show our commitment to delivering a= gainst these key patient needs.=E2=80=9D Reflecting UCB=E2=80=99s efforts to better understand the impact of psorias= is on patients, and the unique needs of women, UCB will present new results= from a sample of almost 90,000 respondents of the World Psoriasis Happines= s Surveys. These findings highlight gender as a strong predictor of psychol= ogical and social well-being in people living with psoriasis and PsA, more = so than geographies. The analysis illustrates how psoriasis and PsA can neg= atively affect women more than men when it comes to life satisfaction, lone= liness, mood and self-esteem. Worse life satisfaction, stress, loneliness a= nd isolation were felt most in young women with psoriasis. New CIMZIA three-year efficacy data in plaque psoriasis from a pooled analy= sis of the completed CIMPASI-1 and CIMPASI-2 open-label extension Phase 3 s= tudies will be presented as an oral presentation at EADV 2019;^1 CIMZIA=E2= =80=99s safety profile remains consistent with previously reported data.^1 = Additional pooled results from these trials include CIMZIA 48-week sustaine= d efficacy data in psoriasis of the head and neck, areas where disease mani= festations can cause high degrees of emotional distress, particularly for f= emale patients.^7 A post-hoc analysis of the four-year RAPID-PsA study will= also be highlighted, showing durability of response of CIMZIA in PsA.^2 Th= e ongoing focus on researching the long-term efficacy and safety of CIMZIA = demonstrates how UCB continues its ongoing commitment to improving the live= s of people with psoriasis. New 60-week data on novel investigational molecule bimekizumab, from the BE= ABLE Phase 2 clinical development program, will be shared in an oral prese= ntation. The findings show rapid and sustained improvements in quality of l= ife (as measured by the Dermatology Life Quality Index), which positively a= ssociate with clinical outcomes in patients with moderate-to-severe plaque = psoriasis.^3 Positive scalp and nail disease outcomes at 60 weeks will also= be presented, further supporting bimekizumab=E2=80=99s potential.^4 The safety and efficacy of bimekizumab have not been established, and it is= not approved by any regulatory authority worldwide. Following is a guide to the UCB-sponsored data presentations: UCB Sponsored Symposia: Consider Tomorrow in Today=E2=80=99s Treatment Choice for Women Living with= Psoriasis, M. Augustin, S. McBride, A. Egeberg =C2=B7 Date/Time: October 10, 2019: 17:00-18:30 CEST =C2=B7 Location: Hall Sorolla Uncovering the potential of IL-17A and IL-17F dual neutralization in psoria= sis, K. Papp, A. Armstrong, L. Iversen =C2=B7 Date/Time: October 11, 2019: 17:00-18:30 CEST =C2=B7 Location: Hall Sorolla CIMZIA Oral Presentations: Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Eff= icacy Outcomes from the Intent-to-Treat Population of Two Phase 3 Trials (C= IMPASI-1 and CIMPASI-2), K. Gordon, R. Warren, A. Gottlieb, A. Blauvelt, D.= Tha=C3=A7i, C. Leonardi, Y. Poulin, M. Boehnlein, S. Kavanagh, C. Arendt, = K. Reich =C2=B7 Date/Time: October 10, 2019: 11:35-11:45 CEST =C2=B7 Location: N109-110 Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Bu= rden and Their Influence on the Safety Profile of Certolizumab Pegol across= Indications, A. Blauvelt, V. Bykerk, J. Curtis, C. Gaujoux-Viala, T. Kvien= , W. Sandborn, K. Winthrop, C. Popova, X. Mariette =C2=B7 Date/Time: October 10, 2019: 15:50-16:00 CEST =C2=B7 Location: N109-110 CIMZIA e-Posters: Durability of Response in Patients with Psoriatic Arthritis Treated with Ce= rtolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study= , A. Gottlieb, P. Gisondi, J. Eells, L. Peterson, A. Kavanaugh Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Ph= ase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2, P. van de Kerkhof, A. Pinte= r, M. Boehnlein, S. Kavanagh, J. Crowley Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in= Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Tria= ls (CIMPASI-1 and CIMPASI-2), K. Gordon, R. Warren, A. Gottlieb, A. Blauvel= t, D. Tha=C3=A7i, C. Leonardi, Y. Poulin, M. Boehnlein, S. Kavanagh, C. Are= ndt, K. Reich Efficacy and Safety of Certolizumab Pegol in the Treatment of Japanese Pati= ents With Psoriasis: Interim Week 24 Analyses from a 52-Week Phase 2/3, Ran= domised, Placebo-Controlled Study, A. Asahina, Y. Umezawa, S. Sakurai, N. H= oshii, H. Nakagawa Bimekizumab Oral Presentations: Bimekizumab provides rapid and sustained improvements in quality of life th= at correlate with clinical outcomes in patients with moderate to severe pla= que psoriasis: 60-week results from a randomised, double-blinded, Phase 2b = extension study, K. Papp, J. Merola, A. Gottlieb, C. Griffiths, K. Harris, = N. Cross, L. Peterson, C. Cioffi, A. Blauvelt =C2=B7 Date/Time: October 10, 2019: 10:25-10:35 CEST =C2=B7 Location: N109-110 Bimekizumab e-Poster: Bimekizumab provides rapid and sustained improvements in scalp and nail out= comes in patients with moderate-to-severe plaque psoriasis: 60-week results= from a randomised, double-blinded, Phase 2b extension study, A. Blauvelt, = K. Papp, J. Merola, A. Gottlieb, N. Cross, C. Madden, L. Peterson, C. Cioff= i, C. Griffiths UCB-Sponsored e-Poster on the Effect of Gender on the Impact of psoriasis: Gender Differences in the Impact of Psoriasis: Results from the World Psori= asis Happiness Surveys, S. McBride, C. Ecoffet, F. Fierens, M. Birkj=C3=A6r About Bimekizumab Bimekizumab is an investigational novel humanized monoclonal IgG1 antibody = that potently and selectively neutralizes both IL-17A and IL-17F, two key c= ytokines driving inflammatory processes.^8 IL-17A and IL-17F have similar p= ro-inflammatory functions and independently cooperate with other inflammato= ry mediators to drive chronic inflammation and damage across multiple tissu= es. Previous early phase clinical studies in psoriasis and psoriatic arthritis = have suggested that bimekizumab=E2=80=99s dual neutralization of both IL-17= A and IL-17F may provide a new targeted approach for the treatment of immun= e-mediated inflammatory diseases.^5,8,9 Preclinical results in disease-rele= vant cells have shown that neutralizing IL-17F in addition to IL-17A reduce= s skin and joint inflammation, as well as pathological bone formation to an= extent greater than inhibition of IL-17A alone.^9,10,11 The safety and efficacy of bimekizumab have not been established, and it is= not approved by any regulatory authority worldwide. About CIMZIA^=C2=AE in the EU/EEA In the EU, CIMZIA^=C2=AE in combination with methotrexate (MTX) is indicate= d for the treatment of moderate to severe active RA in adult patients inade= quately responsive to disease-modifying anti-rheumatic drugs (DMARDs) inclu= ding MTX. CIMZIA can be given as monotherapy in case of intolerance to MTX or when co= ntinued treatment with MTX is inappropriate. CIMZIA in combination with MTX= is also indicated for the treatment of severe, active and progressive RA i= n adults not previously treated with MTX or other DMARDs. CIMZIA has been shown to reduce the rate of progression of joint damage as = measured by X-ray and to improve physical function, when given in combinati= on with MTX. CIMZIA, in combination with MTX, is also indicated for the treatment of act= ive psoriatic arthritis in adults when the response to previous DMARD thera= py has been inadequate. CIMZIA can be given as monotherapy in case of intol= erance to MTX or when continued treatment with MTX is inappropriate. CIMZIA is also indicated in the EU for the treatment of adult patients with= severe active axial spondyloarthritis (axSpA), comprising: =C2=B7 Ankylosing spondylitis (AS) =E2=80=93 adults with severe active AS w= ho have had an inadequate response to, or are intolerant to non-steroidal a= nti-inflammatory drugs (NSAIDs). =C2=B7 Axial spondyloarthritis (axSpA) without radiographic evidence of AS = =E2=80=93 adults with severe active axSpA without radiographic evidence of = AS but with objective signs of inflammation by elevated C-reactive protein = (CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate re= sponse to, or are intolerant to NSAIDs. CIMZIA is also indicated for the treatment of moderate to severe plaque pso= riasis in adults who are candidates for systemic therapy. About CIMZIA^=C2=AE in Fertility, Pregnancy and Lactation in the EU/EEA Women of childbearing potential The use of adequate contraception should be considered for women of childbe= aring potential. For women planning pregnancy, continued contraception may = be considered for 5 months after the last CIMZIA dose due to its eliminatio= n rate, but the need for treatment of the woman should also be taken into a= ccount (see below). =C2=A0 Pregnancy Data from more than 500 prospectively collected pregnancies exposed to CIMZ= IA with known pregnancy outcomes, including more than 400 pregnancies expos= ed during the first trimester, does not indicate a malformative effect of C= IMZIA. However, the available clinical experience is too limited to, with a= reasonable certainty, conclude that there is no increased risk associated = with CIMZIA administration during pregnancy. =C2=A0 Animal studies using a rodent anti-rat TNF=CE=B1 did not reveal evidence of= impaired fertility or harm to the foetus. However, these are insufficient = with respect to human reproductive toxicity. Due to its inhibition of TNF= =CE=B1, CIMZIA administered during pregnancy could affect normal immune res= ponse in the newborn. =C2=A0 CIMZIA should only be used during pregnancy if clinically needed. Non-clini= cal studies suggest low or negligible level of placental transfer of a homo= logue Fab-fragment of certolizumab pegol (no Fc region). =C2=A0 In a clinical study 16 women were treated with certolizumab pegol (200 mg e= very 2 weeks or 400 mg every 4 weeks) during pregnancy. Certolizumab pegol = plasma concentrations measured in 14 infants at birth were Below the Limit = of Quantification (BLQ) in 13 samples; one was 0.042 =C2=B5g/ml with an inf= ant/mother plasma ratio at birth of 0.09%. At Week 4 and Week 8, all infant= concentrations were BLQ. The clinical significance of low levels certolizu= mab pegol for infants is unknown. It is recommended to wait a minimum of 5 = months following the mother's last CIMZIA administration during pregnancy b= efore administration of live or live-attenuated vaccines (e.g. BCG vaccine)= , unless the benefit of the vaccination clearly outweighs the theoretical r= isk of administration of live or live-attenuated vaccines to the infants. =C2=A0 Breastfeeding In a clinical study in 17 lactating women treated with CIMZIA, minimal tran= sfer of certolizumab pegol from plasma to breast milk was observed. The per= centage of the maternal certolizumab pegol dose reaching an infant during a= 24 hour period was estimated to 0.04% to 0.30%. In addition, since certoli= zumab pegol is a protein that is degraded in the gastrointestinal tract aft= er oral administration, the absolute bioavailability is expected to be very= low in a breastfed infant. Consequently, CIMZIA can be used during breastf= eeding. Important Safety Information about CIMZIA^=C2=AE in the EU/EEA Cimzia^=C2=AE was studied in 4,049 patients with rheumatoid arthritis (RA) = in controlled and open label trials for up to 92 months. The commonly repor= ted adverse reactions (1-10%) in clinical trials with Cimzia^=C2=AE and pos= t-marketing were viral infections (includes herpeszoster, papillomavirus, i= nfluenza), bacterial infections (including abscess), rash, headache (includ= ing migraine), asthaenia, leukopaenia (including lymphopaenia, neutropaenia= ), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalities,= hypertension, pruritus (any sites), hepatitis (including hepatic enzyme in= crease), injection site reactions, and nausea. Serious adverse reactions in= clude sepsis, opportunistic infections, tuberculosis (including miliary, di= sseminated and extrapulmonary), herpes zoster, lymphoma, leukaemia, solid o= rgan tumours, angioneurotic oedema, cardiomyopathies (includes heart failur= e), ischemic coronary artery disorders, pancytopaenia, hypercoagulation (in= cluding thrombophlebitis, pulmonary embolism), cerebrovascular accident, va= sculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairment/= nephropathy (includes nephritis). In RA controlled clinical trials, 4.4% of= patients discontinued taking Cimzia^=C2=AE due to adverse events vs. 2.7% = for placebo. Cimzia^=C2=AE is contraindicated in patients with hypersensitivity to the a= ctive substance or any of the excipients, active tuberculosis or other seve= re infections such as sepsis or opportunistic infections and moderate to se= vere heart failure. Serious infections including sepsis, tuberculosis and opportunistic infecti= ons (e.g. histoplasmosis, nocardia, candidiasis) have been reported in pati= ents receiving Cimzia^=C2=AE. Some of these events have been fatal. Monitor= patients closely for signs and symptoms of infections including tuberculos= is before, during and after treatment with Cimzia^=C2=AE. Treatment with Ci= mzia must not be initiated in patients with a clinically important active i= nfection. If an infection develops, monitor carefully and stop Cimzia^=C2= =AE until the infection is controlled. Before initiation of therapy with Ci= mzia^=C2=AE, all patients must be evaluated for both active and inactive (l= atent) tuberculosis infection. If active tuberculosis is diagnosed prior to= or during treatment, Cimzia^=C2=AE therapy must not be initiated and must = be discontinued. If latent tuberculosis is diagnosed, appropriate anti-tube= rculosis therapy must be started before initiating treatment with Cimzia^= =C2=AE. Patients should be instructed to seek medical advice if signs/sympt= oms (e.g. persistent cough, wasting/weight loss, low grade fever, listlessn= ess) suggestive of tuberculosis occur during or after therapy with Cimzia^= =C2=AE. Reactivation of hepatitis B has occurred in patients receiving a TNF-antago= nist including Cimzia^=C2=AE who are chronic carriers of the virus (i.e. su= rface antigen positive). Some cases have had a fatal outcome. Patients shou= ld be tested for HBV infection before initiating treatment with Cimzia^=C2= =AE. Carriers of HBV who require treatment with Cimzia^=C2=AE should be clo= sely monitored and in the case of HBV reactivation Cimzia^=C2=AE should be = stopped and effective anti-viral therapy with appropriate supportive treatm= ent should be initiated. TNF antagonists including Cimzia^=C2=AE may increase the risk of new onset = or exacerbation of clinical symptoms and/or radiographic evidence of demyel= inating disease, including multiple sclerosis; of formation of autoantibodi= es and uncommonly of the development of a lupus-like syndrome; of severe hy= persensitivity reactions. If a patient develops any of these adverse reacti= ons, Cimzia^=C2=AE should be discontinued and appropriate therapy institute= d. With the current knowledge, a possible risk for the development of lymphoma= s, leukaemia or other malignancies in patients treated with a TNF antagonis= t cannot be excluded. Rare cases of neurological disorders, including seizu= re disorder, neuritis and peripheral neuropathy, have been reported in pati= ents treated with Cimzia^=C2=AE. Adverse reactions of the haematologic system, including medically significa= nt cytopaenia, have been reported with Cimzia^=C2=AE. Advise all patients t= o seek immediate medical attention if they develop signs and symptoms sugge= stive of blood dyscrasias or infection (e.g., persistent fever, bruising, b= leeding, pallor) while on Cimzia^=C2=AE. Consider discontinuation of Cimzia= ^=C2=AE therapy in patients with confirmed significant haematological abnor= malities. The use of Cimzia^=C2=AE in combination with anakinra or abatacept is not r= ecommended due to a potential increased risk of serious infections. As no d= ata are available, Cimzia^=C2=AE should not be administered concurrently wi= th live vaccines. The 14-day half-life of Cimzia^=C2=AE should be taken int= o consideration if a surgical procedure is planned. A patient who requires = surgery while on Cimzia^=C2=AE should be closely monitored for infections. Cimzia^=C2=AE was studied in 325 patients with active axial spondyloarthrit= is (axSpA) and in 409 patients with psoriatic arthritis (PsA) for up to 4 y= ears. The safety profile for axSpA and PsA patients treated with Cimzia^=C2= =AE was consistent with the safety profile in RA and previous experience wi= th Cimzia^=C2=AE. Cimzia^=C2=AE was studied in 1112 patients with psoriasis in controlled and= open-label studies for up to 18 months. The safety profile of Cimzia^=C2= =AE 400 mg every 2 weeks and Cimzia^=C2=AE 200 mg every 2 weeks were genera= lly similar. Please consult the full prescribing information in relation to other side e= ffects, full safety and prescribing information. European SmPC date of revi= sion June 2019. https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-= 2F12d8lSllQB1bgRcJUw8Y6HnHitlehmUp9p23N1ICSEkr9hUTj0vim7zTMmQo26bK8O-2BjuX8= 8sB9OJdL3Ci054qpQT9GBqra6-2FDw0ibG27mjCbSf4S7UMr8wRWh71-2BkIG4oncCRyEopQ-3D= -3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hT= xd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACRMW7oN5ofytBygtIFD3oaokb2us3k7AJy44= 1T7WNxPPVTv821BriKESvLaQypbwTNG2Lk7UYD-2FkK-2BhyeslUT59CViG1HmxaAGzYhd36-2F= 3qk8KE5hZKpWUCIchCpBeV-2BogY5RLFP-2FG4-2FvHIQIUxNzrSSswJ3wwhXIHFmtSAow-2Fcq= O6U0fueQT3qMrEMiIkzDQfwCeo4lpwO-2BI4odmE3bc2e6IHj6CrbdXH18vyErizowiM4zkN5Aq= JS5EgkTloVDg-3D CIMZIA^=C2=AE is a registered trademark of the UCB Group of Companies. For further information, UCB: Corporate Communications France Nivelle, Global Communications, UCB T +32.2.559.9178 france.nivelle@ucb.com Laurent Schots, Media Relations, UCB T +32.2.559.92.64 laurent.schots@ucb.com Investor Relations Antje Witte, Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Communications Lead Andrea Levin Christopher, Immunology Communications, UCB T +1.404.483.7329 andrea.christopher@ucb.com=C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases in immunol= ogy and neurology. With 7,500 people in approximately 40 countries, the com= pany generated revenue of =E2=82=AC 4.6 billion in 2018. UCB is listed on E= uronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Forward looking statements - UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees. UCB is providing this information as of the date of this press r= elease and expressly disclaims any duty to update any information contained= in this press release, either to confirm the actual results or to report a= change in its expectations. =C2=A0 There is no guarantee that new product candidates in the pipeline will prog= ress to product approval or that new indications for existing products will= be developed and approved. Products or potential products which are the su= bject of partnerships, joint ventures or licensing collaborations may be su= bject to differences between the partners. Also, UCB or others could discov= er safety, side effects or manufacturing problems with its products after t= hey are marketed. Moreover, sales may be impacted by international and dome= stic trends toward managed care and health care cost containment and the re= imbursement policies imposed by third-party payers as well as legislation a= ffecting biopharmaceutical pricing and reimbursement. ^1Gordon K, et al. Certolizumab Pegol for Treatment of Plaque Psoriasis: Po= oled Three-Year Efficacy Outcomes from the Intent-to-Treat Population of Tw= o Phase 3 Trials (CIMPASI-1 and CIMPASI-2). Abstract to be presented at EAD= V 2019, 9-13 October, Madrid Spain. ^2Gottlieb A, et al. Durability of Response in Patients with Psoriatic Arth= ritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses fro= m the RAPID-PsA Study. Abstract to be presented at EADV 2019, 9-13 October,= Madrid Spain. ^3Papp K, et al. Bimekizumab provides rapid and sustained improvements in q= uality of life that correlate with clinical outcomes in patients with moder= ate to severe plaque psoriasis: 60-week results from a randomised, double-b= linded, Phase 2b extension study. Abstract to be presented at EADV 2019, 9-= 13 October, Madrid Spain. ^4Blauvelt A, et al. Bimekizumab provides rapid and sustained improvements = in scalp and nail outcomes in patients with moderate-to-severe plaque psori= asis: 60 week results from a randomised, double-blinded, Phase 2b extension= study. Abstract to be presented at EADV 2019, 9-13 October, Madrid Spain. ^5Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation = by bimekizumab in psoriatic arthritis: evidence from preclinical experiment= s and a randomized placebo-controlled clinical trial that IL-17F contribute= s to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523-532. ^6McBride S, et al. Gender Differences in the Impact of Psoriasis: Results = from the World Psoriasis Happiness Surveys. Abstract to be presented at EAD= V 2019, 9-13 October, Madrid Spain. ^7van de Kerkhof P, et al. Efficacy of Certolizumab Pegol for Psoriasis of = the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2. = Abstract to be presented at EADV 2019, 9-13 October, Madrid Spain. ^8Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bim= ekizumab, a humanized monoclonal antibody and selective dual inhibitor of I= L-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-10= 01. ^9Papp K, Merola J, Gottlieb A, Griffiths C, Cross N, Peterson L, Cioffi C,= Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17= F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12= -week randomized, double-blinded, placebo-controlled phase 2b trial. J Am A= cad Dermatol. 2018;79(2):277-286.e10. ^10Shah M, Maroof A, Al-Hosni R, Gikas P, Gozzard N, Shaw S, Roberts S. Bim= ekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal St= em Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signali= ng [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). ^11Maroof A, Okoye R, Smallie T, et al. Bimekizumab dual inhibition of IL-1= 7A and IL-17F provides evidence of IL-17F contribution to chronic inflammat= ion in disease-relevant cells. Ann Rheum Dis. 2017;76(suppl.2):213-213. GenericFile UCB Showcases Wealth of new Psoriasis Research at EADV 2019 (https://u70611= 46.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6H= nxedhbf51v5xTz8YVKU3FhdBqvjhUnCDkjpeJl16bKFIwhH9LE80b0b4aoTk1Lj5xo2A-3D_-2B= -2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7r= BLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACRMW7oN5ofytBygtIFD3oaokb2us3k7AJy441T7WNxP= PVTv821BriKESvLaQypbwTNG2Lk7UYD-2FkK-2BhyeslUT59CViG1HmxaAGzYhd36-2F3qux7RY= CV4OYFWdiml9LDvsTwaFygouY7bqS45D28G0uzBJpoW-2Bj0T9hyS9l-2F6HCQBles2T95YKAqf= 0xvJmiMlL-2Bsct7Alc2v70E-2FCDOsTgOWP8e9-2BFAavp-2FV1SXzYgprAL7ALrLOFj1sKbDz= rE5JEUE-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQ= Bz2p53T0v-2BoEIvbo6vDi8C-2BOyFzyb6obo-2BzKSgNKq4mrKUeMBpjiYB1cQsyTmxzWMOAHN= qno2-2B8qzsW00Hirtya6dUP5-2FV2s6cX84SPl2jiQaWHE0kD2d0s5N6tMtJ5TTQ-2BUQXPUcb= Ewz3deojlN9ms-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZT= jzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACRMW7oN5ofytBygtIFD3oao= kb2us3k7AJy441T7WNxPPVTv821BriKESvLaQypbwTNG2Lk7UYD-2FkK-2BhyeslUT59CViG1Hm= xaAGzYhd36-2F3qrIkwBesu728r2ENya-2FZKwVAoKglaXt-2BLit2Kx0c-2FE6I-2B-2Fka2oE= QRExQRF3gO-2BdqdOSA0rWodJwbS44NuzY4pcRWNPOC5j-2BoqH5VGaf3Z2gVKGkM66XXyAEc5O= -2BcQLmOfvGa38iYPkCguiiaDtevDBo-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

07/07/2020 19:00
03/07/2020 20:00
26/06/2020 20:00
19/06/2020 20:00
16/06/2020 07:01
12/06/2020 21:00
11/06/2020 20:00
05/06/2020 07:00
04/06/2020 07:00
02/06/2020 20:00